Search results for "psyc"

showing 10 items of 27156 documents

Determinants of Quality of Life According to Cognitive Status in Parkinson’s Disease

2020

Background: Quality of life (QoL) was worse in Parkinson's disease patients with mild cognitive impairment (PD-MCI) or dementia (PDD) than PD patients with normal cognition (PD-NC). The aim of this study was to investigate and compare the potential heterogeneous determinants of QoL in PD patients with different cognitive statuses. Methods: We recruited 600 PD patients, including 185 PD-NC patients, 336 PD-MCI patients and 79 PDD patients, in this cross-sectional study. All patients completed the QoL assessment by the 39-item Parkinson's Disease Questionnaire (PDQ-39), as well as clinical evaluations and neuropsychological tests. The determinants of the QoL were analysed by multiple stepwise…

0301 basic medicineAgingmedicine.medical_specialtyParkinson's diseaseCognitive NeuroscienceDiseasebehavioral disciplines and activitieslcsh:RC321-57103 medical and health sciences0302 clinical medicinemild cognitive impairmentQuality of lifeRating scalemental disordersmedicineDementialcsh:Neurosciences. Biological psychiatry. NeuropsychiatryDepression (differential diagnoses)Original Researchbusiness.industryNeuropsychologyCognitiondeterminantsmedicine.diseasehumanitiesnervous system diseases030104 developmental biologyquality of lifePhysical therapyParkinson’s diseasebusinesshuman activities030217 neurology & neurosurgeryNeurosciencedementiaFrontiers in Aging Neuroscience
researchProduct

Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study.

2018

Background: Cognitive impairment in Parkinson's disease (PD) includes a spectrum varying from Mild Cognitive Impairment (PD-MCI) to PD Dementia (PDD). The main aim of the present study is to evaluate the incidence of PD-MCI, its rate of progression to dementia, and to identify demographic and clinical characteristics which predict cognitive impairment in PD patients. Methods: PD patients from a large hospital-based cohort who underwent at least two comprehensive neuropsychological evaluations were retrospectively enrolled in the study. PD-MCI and PDD were diagnosed according to the Movement Disorder Society criteria. Incidence rates of PD-MCI and PDD were estimated. Clinical and demographic…

0301 basic medicineAgingmedicine.medical_specialtyParkinson's diseaseCognitive NeuroscienceParkinson's diseasebehavioral disciplines and activitieslcsh:RC321-57103 medical and health sciences0302 clinical medicinemild cognitive impairmentInternal medicinemental disordersMedicineDementiaNeuropsychological assessmentMild cognitive impairment (MCI)lcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchmedicine.diagnostic_testbusiness.industryProportional hazards modelIncidence (epidemiology)Neuropsychologymedicine.diseasenervous system diseasesneuropsychological assessment030104 developmental biologyCohortParkinson’s diseaseincidencebusiness030217 neurology & neurosurgeryNeurosciencedementiaFrontiers in aging neuroscience
researchProduct

Precuneus Dysfunction in Parkinson's Disease With Mild Cognitive Impairment.

2018

Background: Mild cognitive impairment (MCI) frequently occurs in Parkinson's disease (PD). Neurovascular changes interact with neurodegenerative processes in PD. However, the deficits of cerebral blood flow (CBF) perfusion and the associated functional connectivity (FC) in PD patients with MCI (PD-MCI) remain unclear. Purpose: This study aimed to explore the specific neurovascular perfusion alterations in PD-MCI compared to PD with normal cognition (PD-NC) and healthy controls (HCs), and to further examine the resultant whole brain FC changes in the abnormal perfusion regions. Methods: Relative CBF (rCBF) was calculated using arterial spin labeling (ASL) in 54 patients with PD (27 patients …

0301 basic medicineAgingmedicine.medical_specialtyParkinson's diseaseCognitive NeurosciencePrecuneusParkinson’s disease with mild cognitive impairmentcomputer.software_genrebehavioral disciplines and activitieslcsh:RC321-57103 medical and health sciences0302 clinical medicineprecuneusVoxelInternal medicinemental disordersmedicineCognitive impairmentlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchfunctional connectivity (FC)business.industryNeuropsychologymedicine.diseaseNeurovascular bundleparietal memory networknervous system diseases030104 developmental biologymedicine.anatomical_structureCerebral blood flownervous systemCardiologybusinessPerfusioncomputer030217 neurology & neurosurgeryNeurosciencearterial spin labeling (ASL)Frontiers in aging neuroscience
researchProduct

The Early Indicators of Functional Decrease in Mild Cognitive Impairment

2016

OBJECTIVES: Motor deficiency is associated with cognitive frailty in patients with Mild Cognitive Impairments (MCI). In this study we aimed to test the integrity of the muscle synergy involved in an arm-pointing movement in MCI patients, non-impaired functionally. Thus, we were able to test the hypothesis that early motor indicators exist in this population at a preclinical level. METHODS: The electromyographic signals were collected for 11 muscles in 3 groups: Young Adults (YA), Aged Adults (AA), and MCI patients. The AA and MCI groups presented the same functional status. Each subject performed twenty arm-pointing movements from a standing position. RESULTS: The main differences were (1) …

0301 basic medicineAgingmedicine.medical_specialtycognitive functionsMild Cognitive ImpairmentsCognitive NeurosciencePopulationMotor program[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologylow-back-painarm movementsbehavioral disciplines and activitiesequilibrium03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationpart-bmental disordersmedicinemotor controlvoluntaryolder-adultsYoung adultalzheimers-diseaseeducationMuscle synergyanticipatory postural adjustmentsOriginal Researcheducation.field_of_study[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologymuscle synergyage-related-changesMotor controlCognitionExecutive functionsLow back painnervous system diseases030104 developmental biology[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Physical therapy[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]parkinsons-diseasemedicine.symptomPsychology030217 neurology & neurosurgeryNeuroscience
researchProduct

Does telomere length predict decline in physical functioning in older twin sisters during an 11-year follow-up?

2016

Background: Leucocyte telomere length (LTL) is known to be associated with mortality, but its association with age-related decline in physical functioning and the development of disability is less clear. This study examined the associations between LTL and physical functioning, and investigated whether LTL predicts level of physical functioning over an 11- year follow-up. Methods: Older mono- (MZ) and dizygotic (DZ) twin sisters (n=386) participated in the study. Relative LTL was measured by qPCR at baseline. Physical functioning was measured by 6-min walking distance and level of physical activity (PA). Walking distance was measured at baseline and at 3-year follow-up. PA was assessed by q…

0301 basic medicineAgingmissing data not at randomTwinsphysical activitysix-minute walking testENVIRONMENTAL-FACTORSDevelopmental psychologyPhysical functioningMAXIMAL WALKING SPEEDSix-minute walking testLeukocytesMedicinetwin studyFinlandtelomereHERITABILITYWOMENTwin studyASSOCIATIONGeneral MedicineMiddle AgedTelomere3142 Public health care science environmental and occupational healthSurvival RateCARDIOVASCULAR-DISEASEbiological agingDisease ProgressionFemalePhysical activityfyysinen toimintakykyMotor ActivityArticleBiological aging03 medical and health sciencesWalking distanceAGEDiseases in TwinsHumansMissing data not at randomMotor activityMobility LimitationMETAANALYSISAgedPhysical activitybusiness.industryMORTALITYDisease progressionRepeated measures designHeritabilityTwin study030104 developmental biology3121 General medicine internal medicine and other clinical medicineGeriatrics and GerontologyDANISH TWINSbusinessPhysical functioningDemographyForecasting
researchProduct

The role of (E)-6-chloro-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-styrylquinazolin-4(3H)-one in the modulation of cannabinoidergic system. A pilot stu…

2018

Abstract Background Compounds acting on endocannabinoid system regulate different neuronal processes through the cannabinoid receptors activation. The main aim of this study was determining whether the 2-styrylquinazolin-4(3H)-one 5, a structural analogue of rimonabant, was able to counteract the behavioural signs of the activation of the endocannabinoidergic system induced by CP 55.940. Methods Behavioural assessment was carried out using the tetrad task and the novel object recognition test. The endocannabinoidergic system activation was possible by the administration of CP 55.940 and 30 min after rats were tested in the tetrad task for the evaluation of the antinociceptive-, cataleptic-,…

0301 basic medicineAgonistCannabinoid receptormedicine.drug_classmedicine.medical_treatmentPilot ProjectsPharmacologyCannabinoidergicStyrenes03 medical and health sciences0302 clinical medicineRimonabantmedicineAnimalsRats WistarLatency (engineering)PharmacologyDose-Response Relationship DrugCannabinoid CB1 receptor antagonist Quinazolinone derivate Tetrad task Declarative memoryCannabinoidsChemistryRecognition PsychologyGeneral MedicineCyclohexanolsEndocannabinoid systemSettore CHIM/08 - Chimica FarmaceuticaRats030104 developmental biologyNociceptionQuinazolinesSettore BIO/14 - FarmacologiaCannabinoidLocomotion030217 neurology & neurosurgerymedicine.drug
researchProduct

Effects of Chronic Dopamine D2R Agonist Treatment and Polysialic Acid Depletion on Dendritic Spine Density and Excitatory Neurotransmission in the mP…

2016

Dopamine D2 receptors (D2R) in the medial prefrontal cortex (mPFC) are key players in the etiology and therapeutics of schizophrenia. The overactivation of these receptors contributes to mPFC dysfunction. Chronic treatment with D2R agonists modifies the expression of molecules implicated in neuronal structural plasticity, synaptic function, and inhibitory neurotransmission, which are also altered in schizophrenia. These changes are dependent on the expression of the polysialylated form of the neural cell adhesion molecule (PSA-NCAM), a plasticity-related molecule, but nothing is known about the effects of D2R and PSA-NCAM on excitatory neurotransmission and the structure of mPFC pyramidal n…

0301 basic medicineAgonistMaleDendritic spineArticle SubjectGlycoside Hydrolasesmedicine.drug_classDendritic SpinesPrefrontal CortexNeural Cell Adhesion Molecule L1NeurotransmissionInhibitory postsynaptic potentialbehavioral disciplines and activitiesSynaptic Transmissionlcsh:RC321-571Rats Sprague-Dawley03 medical and health sciences0302 clinical medicineDopamineDopamine receptor D2PhenethylaminesmedicineAnimalslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryChemistryReceptors Dopamine D2Pyramidal CellsGlutamate receptorRats030104 developmental biologyNeurologynervous systemDopamine AgonistsSialic AcidsNeural cell adhesion moleculeNeurology (clinical)Neuroscience030217 neurology & neurosurgerymedicine.drugResearch ArticleNeural plasticity
researchProduct

Subchronic vortioxetine treatment -but not escitalopram- enhances pyramidal neuron activity in the rat prefrontal cortex.

2017

Abstract Vortioxetine (VOR) is a multimodal antidepressant drug. VOR is a 5-HT 3 -R, 5-HT 7 -R and 5-HT 1D -R antagonist, 5-HT 1B -R partial agonist, 5-HT 1A -R agonist, and serotonin transporter (SERT) inhibitor. VOR shows pro-cognitive activity in animal models and beneficial effects on cognitive dysfunction in major depressive patients. Here we compared the effects of 14-day treatments with VOR and escitalopram (ESC, selective serotonin reuptake inhibitor) on neuronal activity in the medial prefrontal cortex (mPFC). Ten groups of rats (5 standard, 5 depleted of 5-HT with p -chlorophenylalanine -pCPA-, used as model of cognitive impairment) were fed with control food or with two doses of …

0301 basic medicineAgonistMalegenetic structuresmedicine.drug_classSerotonin reuptake inhibitorAction PotentialsPrefrontal CortexPharmacologyCitalopramSulfidesPartial agonistPiperazines03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicinemedicinePremovement neuronal activityAnimalsRats WistarSerotonin transporterPharmacologyVortioxetinebiologyPyramidal CellsAntagonistAntidepressive AgentsRats030104 developmental biologybiology.proteinAntidepressantVortioxetinesense organsPsychologyNeuroscience030217 neurology & neurosurgerySelective Serotonin Reuptake InhibitorsNeuropharmacology
researchProduct

GABAA receptors in the ventral tegmental area control the outcome of a social competition in rats

2018

Social dominance can be attained through social competitions. Recent work in both humans and rodents has identified trait anxiety as a crucial predictor of social competitiveness. In addition, the anxiolytic GABAA positive modulator, diazepam, injected either systemically or into the ventral tegmental area (VTA) was shown to increase social dominance. Here, we investigated the impact of pharmacologically targeting GABAA receptors in the VTA for the outcome of a social competition between two unfamiliar male rats, one of them infused with vehicle and the other one with the drug under study. We show that infusion of the GABAA receptor agonist, muscimol, reduced anxiety-like behaviors and enha…

0301 basic medicineAgonistZolpidemmedicine.drug_classgamma-Aminobutyric acid03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicinemedicinePharmacologyBenzodiazepineGABAA receptorbusiness.industrymusculoskeletal neural and ocular physiologyBicucullineVentral tegmental area030104 developmental biologymedicine.anatomical_structurenervous systemMuscimolchemistrybusinessNeurosciencepsychological phenomena and processes030217 neurology & neurosurgerymedicine.drugNeuropharmacology
researchProduct

β(3)‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?

2019

β(3)‐Adrenoceptor agonists are used in the treatment of overactive bladder syndrome. Although the relaxant response to adrenergic stimulation in human detrusor smooth muscle cells is mediated mainly via β(3)‐adrenoceptors, the plasma concentrations of the therapeutic dose of mirabegron, the only clinically approved β(3)‐adrenoceptor agonist, are considerably lower than the EC(50) for causing direct relaxation of human detrusor, suggesting a mechanism of action other than direct relaxation of detrusor smooth muscle. However, the site and mechanism of action of β(3)‐adrenoceptor agonists in the bladder have not been firmly established. Postulated mechanisms include prejunctional suppression o…

0301 basic medicineAgonistmedicine.medical_specialtyAdrenergic receptormedicine.drug_classUrinary BladderAdrenergic beta-3 Receptor Agonistsurologic and male genital diseasesThemed Section: Review Articles03 medical and health sciences0302 clinical medicineTherapeutic indexDesensitization (telecommunications)Internal medicineMedicineAnimalsHumansPharmacologyUrinary bladderRelaxation (psychology)business.industry030104 developmental biologymedicine.anatomical_structureEndocrinologyMechanism of actionReceptors Adrenergic beta-3medicine.symptombusinessMirabegron030217 neurology & neurosurgerymedicine.drug
researchProduct